Satellos Bioscience Inc. ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today ...

Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...

Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

Entrada plans to initiate clinical testing of ENTR-601-44 in Duchenne MD patients amenable to exon 44 skipping later this year.

Lead drug PGN-EDO51 targets a mutation in the dystrophin gene that can be treated by skipping exon 51, making it a potential rival to Sarepta Pharma's Exondys 51 (eteplirsen), which made $454 ...

Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Cumberland Pharmaceuticals今天宣布，其2期临床试验FIGHT DMD获得积极顶线结果。该研究评估了在研创新口服疗法ifetroban治疗杜氏肌营养不良症（DMD）相关心脏疾病的疗效和安全性。心脏疾病是DMD患者的主要死因。新闻稿指出，这项试验是首个专门针对DMD心脏并发症的成功2期临床试验，代表着这一领域的重要突破。

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...

Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares began Tuesday sharply higher. Cumberland, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, ...

Sarepta's gene therapy – like rivals from Pfizer and Solid Biosciences – codes for a shortened form of the dystrophin protein that is deficient in patients with the muscle-wasting disease.